Highest-materiality recent filing
Kymera reports Q1 net loss $69.2M; Gilead licenses KT-200 for $45M milestone
Net loss $69.2M in Q1 2026, vs $65.6M in Q1 2025; cash $1.55B provides runway into 2029.
Kymera Therapeutics amends bylaws to designate federal courts for securities claims
Board approved amendment to Second Amended and Restated Bylaws on March 25, 2026.
Kymera reports FY2025 net loss $311M; cash $1.6B; STAT6 and IRF5 trials advancing
Cash and investments of $1.6B as of Dec 31, 2025, providing runway into 2029.
Kymera Therapeutics enters $500M at-the-market offering agreement with TD Cowen
Agreement allows Kymera to sell up to $500M of common stock through TD Cowen at its discretion.
Kymera reports $1.6B cash; KT-621 Phase 2b AD data by mid-2027, asthma data late-2027
Preliminary cash, cash equivalents and marketable securities of $1.6B as of Dec 31, 2025; runway into 2029.
Kymera prices upsized $602M public offering; net ~$656M for pipeline
Priced 7,000,000 shares at $86.00 per share; gross proceeds $602M.
Kymera reports positive Phase 1b results for oral STAT6 degrader KT-621 in atopic dermatitis
KT-621 achieved 98% median STAT6 degradation in blood and 94% in skin lesions at Day 29 across both dose groups.
Kymera discusses Phase 1b data for KT-621 in atopic dermatitis on Dec 8 call
Oral STAT6 degrader KT-621 BroADen Phase 1b results presented; slide deck furnished.
Kymera Q3 net loss $82.2M; KT-621 Phase 1b AD data due Dec 2025
Net loss $82.2M in Q3 2025 vs $62.5M in Q3 2024; R&D expenses rose to $74.1M.
Kymera Therapeutics appoints Brian Adams as Chief Legal Officer; Ellen Chiniara retires
Ellen Chiniara, Chief Legal Officer, retires effective Sept 3, 2025; departure not due to any disagreement with the company.
Kymera Q2 net loss $76.6M; cash ~$1B; KT-621 Phase 1 data positive; Gilead CDK2 deal up to $750M
Net loss widened to $76.6M in Q2 2025 ($42.1M Q2 2024); R&D spend rose to $78.4M from $59.2M.
Kymera shareholders elect Albers and Baker as Class II directors at 2025 annual meeting
Jeffrey Albers elected with 55,765,189 votes for, 3,142,251 withheld.
Kymera prices $250.8M public offering of common stock and pre-funded warrants
Offering includes 5,044,500 shares at $44.00 and pre-funded warrants for 655,500 shares at $43.9999.
Kymera and Gilead sign option/license deal for CDK2 degraders; up to $750M
Up to $750M total payments including $85M upfront/option exercise payments.
Sanofi to advance Kymera's KT-485 IRAK4 degrader; $20M milestone achieved
Sanofi selects KT-485 for Phase 1 testing in immuno-inflammatory diseases, expected to start next year; KT-474 will not advance.
SAD: >90% mean STAT6 degradation in blood at doses starting at 6.25 mg; ≥75 mg achieved complete degradation.
Kymera presents Phase 1 healthy volunteer data for oral STAT6 degrader KT-621
Hosted conference call on June 2, 2025 to discuss Phase 1 results for KT-621, a first-in-class oral STAT6 degrader.
Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June
Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.
Kymera grants PSUs to key employees with three clinical milestone vesting targets
PSUs vest in three installments: 40% for first milestone, 40% for second, 20% for third.
Kymera Q4 net loss $70.8M, cash $851M; KT-621 Phase 1 data June 2025
Net loss Q4 2024 $70.8M, full year $223.9M; collaboration revenue Q4 $7.4M vs $47.9M YoY.
Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474
Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.
Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology
Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.
Kymera prices $225M offering of common stock and pre-funded warrants
Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.
Kymera Q2 net loss $42.1M, cash $702M; Sanofi expands KT-474 Phase 2
Net loss $42.1M in Q2 2024 vs $38.8M in Q2 2023; revenue from Sanofi collaboration $25.7M.
Sanofi expands KT-474 Phase 2 trials in HS and AD after positive interim data review
Sanofi to expand ongoing Phase 2 trials for KT-474 in hidradenitis suppurativa and atopic dermatitis.
Director Joanna Horobin resigned from board and all committees on June 18, 2024; resignation not due to any disagreement.
Kymera Therapeutics Q1 2024 net loss $48.6M; cash $745M; pipeline progresses
Net loss $48.6M in Q1 2024 vs $40.9M in Q1 2023; collaboration revenue $10.3M.
On February 24, Leigh Morgan, a member of the Board of Directors (the “Board”) of the Company, the Compensation and Talent Committee of the Board, and a member and chair of the Nominating and Corporate Governance Committee of the Board, informed the Company that she does not intend to stand for reelection at the Company’s 2025 annual meeting of shareholders.
On June 18, 2024, Joanna Horobin, M.B., Ch.B. a member of the Board of Directors (the “Board”) of Kymera Therapeutics, Inc. (the “Company”) and the Audit Committee of the Board (the “Audit Committee”) and Nominating and Corporate Governance Committee of the Board (the “Nominating and Corporate Governance Committee”), notified the Company of her resignation from the Board and all committees thereof, effective immediately.
Max materiality 0.90 · Median 0.70 · Most common event other_material